BRCA1 and cancer: The study of Yao et al. [7] was a retrospective review of pathology results and outcomes of 201 BRCA1/2MUT carriers, in USA, treated between 2007 and 2014 (1.3% occult cancer among 150 BRCA1/2MUT carriers [298 breasts] undergoing nipple-sparing PMs).